Gene expression profiling has identified MUC1 as being significantly overexpressed in prostate cancer with poor clinical outcome after radical surgery, but the molecular mechanisms are still unclear. In this paper, we examined whether the genetic variation in MUC1 alters prostate cancer risk and progression. We identified five haplotype-tagging single-nucleotide polymorphisms that describe inherited genetic variation in and around MUC1. Individual single-nucleotide polymorphisms as well as haplotypes were tested for association with prostate cancer risk and prognosis in 2760 cases and 1722 controls from the Swedish population. We found no association between any single-nucleotide polymorphism or haplotype in the MUC1 and risk of prostate cancer. Stratifying for disease severity or age of onset did not alter the results. Moreover, we observed no association with MUC1 variation and prostate cancer-specific survival. Common variants in MUC1 and the surrounding region are not associated with risk or prognosis of prostate cancer in Swedish men.
Introduction
Gene expression profiling has identified mucin 1 (MUC1) as being significantly overexpressed in prostate cancer, particularly in metastasized disease. 1 -3 Owing to its aberrant expression pattern during cancer progression, MUC1 is an appealing diagnostic marker and a promising therapeutic target, 4, 5 but the molecular mechanisms acting are still unclear.
The MUC1 gene encodes a large cell surface molecule (MUC1) normally expressed only on the apical surfaces of the glandular epithelium; 2 however, transformation is associated with loss of polarity and ubiquitous MUC1 expression. 6 Several isoforms of the MUC1 protein have been described, some of which are produced by alternative mRNA splicing, whereas others are determined by a singlenucleotide polymorphism (SNP), rs4072037, located in exon 2. 7 The differential expressions of isoforms have been described in some cancers 8 including ovarian cancer, 9 gastric cancer 10 and breast cancer. 11 We hypothesize that the inherited MUC1 variation, including rs4072037, alters the probability of developing prostate cancer and/or prognosis. We selected five haplotype-tagging SNPs (htSNPs) using the method of haplotype tagging and genotyped them in 2826 prostate cancer patients and 1705 population-based controls originated from a Swedish prostate cancer case -control study (CAPS).
Methods
Case -control study The study population has been described in detail elsewhere. 12 Briefly, we identified and recruited prostate cancer cases from four of the six regional cancer registries in Sweden. The inclusion criterion was biopsy-confirmed (minimum 97% of patients) or cytologically verified adenocarcinoma of the prostate, diagnosed between July 2001 and October 2003. The pathology was carried out by the attending pathologist for each patient and reported to the regional cancer registries. Out of 3648 identified subjects with prostate cancer, 3161 (87%) agreed to participate. DNA samples from blood, TNM stage, Gleason grade and PSA levels at the time of diagnosis were available for 2893 subjects (92%). Control subjects, who were recruited concurrently with case subjects, were randomly selected from the Swedish Population Registry and matched according to the expected age distribution of cases (groups of 5-year intervals) and geographic region. A total of 2149 out of 3153 control subjects (68%) who were invited subsequently agreed to participate in the study. DNA samples from blood were available for 1781 control subjects (83%). Serum PSA levels were measured for all control subjects but were not used as an exclusion variable.
At the time of this study, DNA was analysed for 2760 cases and 1722 controls. Table 1 presents the clinical characteristics of the study subjects. Each subject provided written informed consent. The study received institutional approval from the ethical board of Karolinska Institutet.
Follow-up
We collected information about prostate cancer-specific mortality for each case subject in CAPS. 13 Figure 1 demonstrates the haplotype blocks of the region surrounding MUC1. The figure was generated using Haploview. 17 
SNP genotyping
Genotyping details have been described earlier. 18 Briefly, we used matrix-assisted laser desorption/ionization timeof-flight (MALDI-TOF) mass spectrometry (Sequenom Inc., San Diego, CA, USA). 19 PCR assays and associated extension reactions were designed using the SpectroDESIGNER software (Sequenom Inc). Primer sequences are available on request. 
Statistical methods
We tested for Hardy -Weinberg equilibrium for each SNP using a replication method as implemented in the GENETICS package in the publicly available software R. 20 The association between prostate cancer risk and each SNP was assessed using a likelihood-ratio test of a covariate equal to the number of rare alleles (0, 1 or 2) based on an unconditional logistic regression model as implemented in R. We used the HAPLO.STATS package 21 in R to test the association between MUC1 haplotypes and prostate cancer risk. Haplotypes with a frequency o5% were pooled together. We adjusted all analyses for age and geographical region. The Follow-up began at the date of diagnosis and ended at the date of death or last follow-up (1 March 2007) . A likelihood-ratio test of a covariate equal to the number of rare alleles (0, 1 or 2) based on the Cox proportional hazards model was used to test the association between SNP and prostate cancer-specific death. To estimate haplotypic effects on survival, we used the THESIAS software, which allows analysis of censored data using a standard Cox proportional hazards formulation. 22 Hazard ratios and corresponding confidence intervals were estimated for each haplotype by comparison to a reference haplotype chosen as the most frequent one. A likelihoodratio test was used to perform a global test of association between haplotypes and prostate cancer death. Effects associated with rare haplotypes (frequency o0.05) were not estimated. All P-values are based on two-sided tests. All analyses were performed in R and Statistica (Statsoft, USA).
Results
Genotyping failed for two selected htSNPs, rs4072037 and rs3814316. To maintain a high coverage of the genetic MUC1 SNPs in prostate cancer RJ Strawbridge et al variation in the region, we genotyped two additional SNPs, rs11264341 and rs2990245. The LD blocks and selected htSNPs are demonstrated in Figure 1 . rs364897 was monomorphic and thus not further analysed. Average genotyping success for the successfully analysed SNPs was 98.1% (range: 96.9-99.2%). The concordance rate between duplicated samples (N ¼ 320) was 100%. Among the controls, all SNPs were in Hardy-Weinberg equilibrium (P40.05).
Association analysis
None of the five SNPs analysed demonstrated a significant difference in genotype frequencies (Table 2) between controls and cases, and thus none were associated with prostate cancer. Stratification for disease severity or age of onset did not alter the results. When grouped as sporadic, hereditary or familial cases, no associations were observed. Four htSNP haplotypes had frequencies above 5% in the controls, with a cumulative frequency above 94% (Table 3) . A global test of association between MUC1 haplotypes and prostate cancer risk was not significant (global P ¼ 0.95, Table 3 ); nor were tests for specific haplotypes significant (Table 3) .
Survival analysis
We observed no association between single SNPs (Table 2) or haplotypes (global P ¼ 0.94, Table 3 ) with prostate cancer-specific survival. This strongly suggests that the genetic variation in the MUC1 region does not alter the probability of developing lethal prostate cancer.
Discussion
This is the first study to investigate the genetic variation in MUC1, the products of which have potential as biomarkers for prostate cancer. These results also indicate that the genetic variation in a region of 40 kb surrounding MUC1 is not associated with prostate cancer. As there are several other coding sequences in the vicinity of MUC1, other genes are potentially affected by the chosen SNPs (Figure 1 ). Of note, none of these other genes have previously been evaluated for the association with prostate cancer.
In addition to splicing/genetic determination of various isoforms influencing the MUC1 protein, post-translational modifications may also contribute to functional differences, 23 as is the case for breast cancer. 5 Therefore, it is feasible that the situation is similar in the prostate, with glycosylation (and other modification) patterns being altered between normal and tumour tissues. The level of MUC1 expression has been reported to be associated with prostate cancer death. 24 However, no information was given on the isoforms assessed, so it remains to be Although rs4072037 failed in our analysis, we genotyped the adjacent rs2066981 marker in strong LD with rs4072037 (r 2 ¼ 0.96), thus providing basically the same genetic information. We, however, observed no correlation between rs2066981 and prostate cancer risk or survival. Previous studies on MUC1 variants in cancer have analysed mRNA expression patterns in tissue from the relevant organ. The variants (determined by rs4072037) observed in ovarian cancer 9 and breast cancer cell lines 11 were predominantly associated with the G-allele. In contrast, genomic DNA from blood samples was analysed in this study. The only other report on MUC1 variants stemming from this SNP in prostate cancer 25 demonstrated the loss of heterozygosity between blood and tumour DNA, with the G-allele being lost. Thus, it may be that the regulation of rs4072037 variants occurs in a tissue-and disease-specific manner. The study population used has a power of 85% to detect the association of an SNP with minor allele frequency of 0.2 and an odds ratio of 1.3 (assuming an additive inheritance model). Our large sample size makes CAPS a well-powered study with a high probability of detecting a true casual allele through the association. Therefore, we believe that this is a true negative finding.
In summary, the genetic variation in 40 Kb surrounding MUC1 does not influence the risk of prostate cancer, disease severity or prostate cancer-specific survival.
